Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,830 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT04722978RecruitingPhase 3
Chemo plus moxifloxacin for metastatic triple-negative breast cancer
This trial tests whether adding moxifloxacin (an antibiotic) to standard chemotherapy helps people with metastatic triple-negative breast cancer live longer or respond better. You may qualify if your cancer has the right lab markers and you haven’t had treatment for metastatic disease yet.
Guangzhou, GuangdongAges 18–70 - NCT05430373RecruitingPhase 1
Injection study for advanced solid tumors using tumor-fighting cells
This Phase 1 trial tests GT101, an injection made from your own tumor-fighting immune cells, for advanced solid cancers that can’t be removed with surgery. It’s mainly aimed at checking safety and early signs of whether the treatment may work.
Beijing, Beijing MunicipalityAges 18–70 - NCT05423262RecruitingPhase 1/Phase 2
TRK-950 for advanced solid tumors that standard treatment can’t control
This trial tests TRK-950 in people with advanced (locally advanced or metastatic) solid tumors when standard treatments have stopped working or aren’t available. It may help by trying a new treatment approach when current options are limited.
Nagoya, Aichi-kenAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT05443126RecruitingPhase 1/Phase 2
Testing a new RET drug for advanced lung cancer
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Loma Linda, CaliforniaAges 18 years+ - NCT05441163Recruiting
Nutrition and exercise program for frail advanced digestive cancer patients
This study tests whether a personalized plan for food (nutrition) and safe, adapted exercise can improve care in frail people with advanced digestive cancers. You may be more likely to feel stronger and better supported during first-line cancer treatment.
Tours, Institut CurieAges 18 years+ - NCT05443087Recruiting
Checking blood levels of targeted drugs for digestive cancers
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
AmiensAges 18 years+ - NCT05419076RecruitingPhase 2
SRS radiation for small cell lung cancer with brain spread
This Phase 2 trial tests a type of focused radiation (stereotactic radiosurgery, or SRS) for people with small cell lung cancer that has spread to the brain. It looks at whether this approach can treat brain metastases when the cancer has limited to a certain number of spots.
Basking Ridge, New JerseyAges 18 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+ - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+ - NCT05410145RecruitingPhase 1/Phase 2
Study drug for advanced KRAS G12C solid tumors
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Orange, CaliforniaAges 18 years+ - NCT05398861RecruitingPhase 2
Testing utidelone plus bevacizumab for HER2-negative advanced breast cancer
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
Zhengzhou, HenanAges 18–70 - NCT05371132RecruitingPhase 1
PET scan study to track immune response after SBRT
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Duarte, CaliforniaAges 18 years+ - NCT05404139RecruitingPhase 2
Short hormone therapy and radiation for prostate cancer that has spread a little
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
Toronto, OntarioAges 18–100 - NCT05378334Recruiting
Test herbal treatment for lung cancer spread to bone
This trial studies whether the herbal medicine HGXJT can improve outcomes and safety for people with non-small cell lung cancer that has spread to the bones. It is designed for a specific lung cancer type (EGFR and ALK wild type) and people who have not had certain immune treatments before.
Guangzhou, GuangdongAges 18–75 - NCT05388773RecruitingPhase 2
Surgery then lower-dose radiation for p16+ throat cancer
This Phase 2 study tests whether removing the tumor through the mouth, followed by a reduced course of radiation, can control HPV-related (p16+) oropharynx throat cancer. It may help reduce treatment intensity after surgery, while still aiming to keep the cancer from coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT05358548RecruitingPhase 2
Alternating treatment for advanced lung and head-neck cancers
This Phase 2 study tests an approach that alternates treatments for advanced lung cancer or recurrent/metastatic head and neck squamous cell cancer. It may help by improving how well the cancer responds while managing side effects differently than standard back-to-back therapy.
Elizabeth, New JerseyAges 18 years+ - NCT05327465Recruiting
Exercise program for Black men on prostate hormone therapy
This trial tests whether a structured exercise program can improve heart and blood-vessel health in Black men receiving androgen deprivation therapy for prostate cancer. It may help your cardiovascular (heart) health and monitors safety during the program.
Boston, MassachusettsAges 18 years+ - NCT05332002RecruitingPhase 2
Study chemotherapy plus immunotherapy for HER2-negative esophageal cancer
This Phase 2 trial tests a combination treatment called sFOLFOXIRI for advanced esophageal or stomach-area cancer that is HER2-negative. It aims to see how well the treatment works and whether it is safe for people who have not had standard chemotherapy for this metastatic cancer yet.
Hamilton, New JerseyAges 18 years+ - NCT05301101Recruiting
Re-irradiation planning for tumors near previously treated organs
This study tests a more personalized way to plan “re-irradiation,” meaning giving radiation again in an area that was already treated before. It aims to better calculate organ risk to reduce harmful side effects while treating cancer.
Milwaukee, WisconsinAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,830 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.